Abstract:Key PointsMost human cancers exhibit a high degree of intratumour heterogeneity that arises from heritable and stochastic genetic and epigenetic changes, as well as environmental variations within the tumour. Heterogeneous subpopulations that exist within close proximity and compete for limited resources can engage in complex interactions that affect tumorigenesis, disease progression and therapeutic outcomes.Phenotypic changes that arise from subclonal interactions in heterogeneous tumours were observed by cancer biologists very early on. However, as studies mostly focused on cell-autonomous oncogenes and tumour suppressors, investigations into clonal interactions went under the radar for almost three decades. With the increasing recognition of intratumour heterogeneity fuelled by advances in technology, dissecting the mechanistic basis of clonal interactions is now gaining more attention.In addition to the more traditional models that explore clonal interactions strictly from the competitive angle, newer studies are investigating cooperative interactions among subclones that could give rise to novel characteristics and that potentially increase the growth and progression of the tumour.In the absence of proper tools to directly study clonal interactions in patient samples, studies in D. melanogaster, rodents and xenograft systems (using both established cell lines and patient-derived cells) are providing us with mechanistic insights into interclonal crosstalk.Theoretical and mathematical modelling are being used to simulate clonal dynamics under variable circumstances. Although currently far from perfect, these in silico cancer models have already been useful for the design of optimized cancer therapies for the more effective eradication of tumours.Cooperation can be metabolically costly but evolution and survival are more efficient, especially in a changing environment, when diversity and heterogeneity are high. Insights from patient tumours have revealed the presence of multiple independent neoplastic driver subclones that could re-establish tumour heterogeneity after therapy and lead to disease relapse. Furthermore, there is increasing evidence of transient clonal cooperation between neoplastic and benign subclones, which can also lead to tumour recurrence.In order to tackle the ever-evolving populations of tumour cells more effectively and to devise more lasting cures in patients, we must use ecological approaches that take advantage of cooperative tumour-promoting interactions and strategically eliminate them instead of targeting each individual subpopulation.

Tumour heterogeneity and resistance to cancer therapies

Heterogeneity in Primary Tumors and Corresponding Metastases: Could It Provide Us with Any Hints to Personalize Cancer Therapy?

Intratumoral Heterogeneity and EGFR-TKIs Resistance

Tumorigenesis: it takes a village

Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy

Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis

Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future

Clinical implications of intratumor heterogeneity: challenges and opportunities

Epigenomic heterogeneity as a source of tumour evolution

Molecular heterogeneity in breast cancer: State of the science and implications for patient care

Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance

Genetic and non-genetic clonal diversity in cancer evolution

Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression

Intratumor Heterogeneity As an Opportunity for Drug Sensitivity Prediction and Biomarker Discovery.

Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy

Stochastic population dynamics of cancer stemness and adaptive response to therapies

Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment

Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells

A narrative review of tumor heterogeneity and challenges to tumor drug therapy

Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung Cancer